

## Role of SglT2 Inhibitors in Modern Medicine

Shail Jani <sup>2</sup>, Sagar Solanki <sup>2</sup>, Twinkle Rana <sup>2</sup>, Hardik Chaudhary <sup>2</sup>, Farhan Piprani <sup>2</sup>, Mayur Patel <sup>3</sup>, Vivek Solanki <sup>3</sup>, Parth Rathva <sup>3</sup>, Amit Vidja <sup>3</sup>, Krunal Patel <sup>3</sup>, Jayesh Trivedi <sup>1\*</sup>

<sup>1</sup>Hod and Professor in Genreal Medicine Gaims Bhuj, India.

<sup>3</sup>rd Year Resident –General Medicine –Gaims Bhuj, India.

<sup>2</sup>rd Year Resident –General Medicine –Gaims Bhuj, India.

\*Correspondence Author: Jayesh Trivedi, Hod and Professor in Genreal Medicine Gaims Bhuj, India.

Received Date: January 09, 2023 | Accepted Date: January 20, 2023 | Published Date: January 26, 2023

Citation: Aamir Jalal Al-Mosawi (2023), Role of SglT2 Inhibitors in Modern Medicine, *International Journal of Clinical Research and Reports*, 2(1); DOI:10.31579/2835-8295/011

Copyright: © 2023, Jayesh Trivedi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

SGLT2 inhibitor is a new invention in medical practice which has changed the progress and treatment part of life threatening medical conditions like type 2 diabetes mellitus causing chronic kidney disease and end stage renal disease, it has changed the concept of treatment of cardiac failure also with compromised left ventricular ejection fraction and retained left ventricular ejection fraction, in combination of dpp4 inhibitor and metformin as a part of polypill it has shown great results with compliance and economy in control of diabetes mellitus, it does not give rise to exhaustion of islets of beta cells of langerhans as it does not affect the endocrinal function of the pancreas and this combination controls hba1c drastically (1.2) without causing hypoglycemia, thus it becomes a treatment of choice in triple drug therapy as an alternative to glp1 receptor agonist, it can be given in dual therapy treatment, so in cases of diabetes mellitus type 2 with lv dysfunction this becomes a treatment of choice.

**Keywords:** general medicine; chronic kidney; cardiac failure

### Salutary Action of SglT2 Inhibitors

SGLT2 inhibitors are a new group of diabetic medications that lowers the absorption of glucose in the kidney, decrease proteinuria, control blood pressure, and are associated with weight loss. SGLT2 inhibitors give complementary therapy independent of insulin secretion or action with proved glucose-lowering effects. placebo-controlled clinical trials have demonstrated that these medications can decrease cardiovascular death, progression of kidney disease, and all-cause mortality in diabetic and non-diabetic patients. Canagliflozin has shown superiority in primary prevention of atheromatous strokes. Interestingly, SGT2 inhibitors like dapagliflozin have also proven to decrease heart failure admissions and cardiovascular endpoints in non-diabetic patients, suggesting pleiotropic effects. Oxidative stress was also reversed by empagliflozin in porcine endothelial cells by inhibition of nitric oxide formation. It decreases the atherosclerosis and endothelial inflammation thus it reduces HsCrp, it decreases the afterload and preload of heart by diuretic effect and natriuretic effect, it reduces Raas activities, it has a uricosuric action. By acting on the SGLT 1 receptor it reduces the afterload of the heart and helps in the elasticity of the arterial wall, by its indirect effect betahydroxybutrate is also increased which also helps in reducing the afterload, it reduces the glomerular pressure and partially dilates the renal artery, it decreases NHE3, it has known to increase erythropoietin secretion which helps indirectly in the treatment of intractable cardiac failure. By natriuresis it decreases the blood volume and body water and plasma volume, it decreases the albuminuria by more than 90

### Conclusion

SGLT2 inhibitors are potent antidiabetic medications with utility in the treatment of patients with T2DM and heart failure. Furthermore, SGLT2 inhibitors have shown to reduce the progression to advanced forms of kidney disease and its complications. These medications should be in the management of patients with diabetic kidney disease with and without chronic kidney disease as they confer protection against cardiovascular/renal death and improve all-cause mortality. It also prevents secondary cardiac fibrosis due to ASCVD thus it helps in preserving ejection fraction and prevents scar induced resistant cardiac arrhythmias, its role in primary dilated cardiomyopathy is to be established. This can be the first drug of therapy in case of intolerance to metformin along with lifestyle modification

### References

1. Kalyani RR, Lazo M, Ouyang P et al. (2013), Gender differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. *Diabetes Care*. 2013 Oct 31.
2. Haffner SM, Lehto S, Ronnema T, et al. (1998), Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*; 339(4):229–34.
3. Bell DS. (2003), Heart failure: the frequent, forgotten, and often fatal complication of diabetes. *Diabetes Care*; 26(8):2433–2441.
4. Arow M., Waldman M., Yadin D., Nudelman V., Shainberg A., Abraham N. G. et al. (2020), Sodium–glucose cotransporter 2

- inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc. Diabetol.
5. Briasoulis A., Al Dhaybi O. and Bakris G. L. (2018), SGLT2 inhibitors and mechanisms of hypertension. J. Curr. Cardiol. Rep. 19, 20–40
  6. DeFronzo R. A. (2017), Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes. Metab.
  7. Dziuba J., Alperin P., Racketa J., Iloje U., Goswami D., Hardy E. et al. (2014), Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes. Metab.

**Ready to submit your research? Choose ClinicSearch and benefit from:**

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

**At ClinicSearch, research is always in progress.**

Learn more <https://clinicsearchonline.org/journals/international-journal-of-clinical-reports-and-studies>



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.